United States· US:0006-3856_11f74255-d000-4759-a561-136a5f13f667
RECARBRIO
A imipenem, cilastatin and relebactam product containing imipenem anhydrous; cilastatin; relebactam anhydrous, registered in United States by Merck Sharp & Dohme LLC. The same ATC class is registered in 11 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Imipenem, cilastatin and relebactam is registered in 11 of 19 countries.
Countries holding a registration under ATC J01DH56 (imipenem, cilastatin and relebactam), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 7 of them publish a price we can compare per daily dose
Imipenem, cilastatin and relebactam · ATC J01DH56
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- IMIPENEM ANHYDROUS; CILASTATIN; RELEBACTAM ANHYDROUS
- Manufacturer
- Merck Sharp & Dohme LLC
- Country
- United States (US)
- ATC code
- J01DH56
- ATC class
- Imipenem, cilastatin and relebactam
- Defined daily dose
- 2 g, P
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc11000638560225 VIAL, SINGLE-DOSE in 1 CARTON (0006-3856-02) / 20 mL in 1 VIAL, SINGLE-DOSE (0006-3856-01)
- ndc110006-3856-02
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Imipenem, cilastatin and relebactam in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NorwayRecarbrioMerck Sharp & Dohme B.V. (1)
- SpainRECARBRIO 500 mg/500 mg/250 mg POLVO PARA SOLUCION PARA PERFUSIONMerck Sharp & Dohme B.V.
- FinlandRecarbrioMerck Sharp & Dohme B.V.
- FranceRECARBRIO 500 mg/500 mg/250 mg, poudre pour solution pour perfusionMERCK SHARP & DOHME (PAYS-BAS)
- United KingdomRecarbrio 500mg/500mg/250mg powder for solution for infusion vialsMerck Sharp & Dohme (UK) Ltd
- IrelandRecarbrio 500 mg/500 mg/250 mg powder for solution for infusionMerck Sharp & Dohme BV,
- NetherlandsRecarbrio 500 mg/500 mg/250 mg, poeder voor oplossing voor infusieMerck Sharp & Dohme B.V.
- CzechiaRECARBRIOMerck Sharp & Dohme B.V., Haarlem
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Recarbrio
- Liechtenstein · Recarbrio
- Norway · Recarbrio
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0816e18a-f0d2-40a8-acc9-b84f4668e1a6 GET /v1/drugs/0816e18a-f0d2-40a8-acc9-b84f4668e1a6?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": "500; 500; 250",
"substance": "IMIPENEM ANHYDROUS; CILASTATIN; RELEBACTAM ANHYDROUS",
"productndc": "0006-3856",
"dosage_form": "INJECTION, POWDER, FOR SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/100mL; mg/100mL; mg/100mL",
"application_number": "NDA212819",
"marketing_category": "NDA"
}See everything about imipenem, cilastatin and relebactam.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.